This trial is testing a new combination of drugs to treat breast cancer, specifically looking at whether it is effective against HER2 positive breast cancer.
1 Primary · 4 Secondary · Reporting Duration: 2 years
Experimental Treatment
45 Total Participants · 1 Treatment Group
Primary Treatment: Gemcitabine · No Placebo Group · Phase 2
Age 18+ · Female Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: